Treatment-Induced Autophagy Associated with Tumor Dormancy and Relapse
Abstract
Despite advances in cancer therapeutics over recent decades, developing effective strategies for the treatment of triple negative breast cancer (TNBC) continues to represent a significant challenge. Cytotoxic chemotherapies that often include doxorubicin (Adriamycin) remain the standard of care in breast cancer; while generally successful, patients frequently relapse with therapy resistant disease. Immunotherapy has emerged as a treatment modality with great promise, but has seen limited success in breast cancer therapy due, in large part,to the low immunogenicity of breast cancer cells. In view of the fact that doxorubicin has been shown to improve tumor immunogenicity by promoting the secretion of damage-associated molecular pattern (DAMP) molecules and immunogenic cell death (ICD), our recent goals were to enhance sensitivity to chemotherapy by both cell autonomous and cell non-autonomous strategies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2017
- Accession Number
- AD1047605
Entities
People
- David A. Gewirtz
Organizations
- Virginia Commonwealth University